31 August 2022FeaturesJurisdiction reportsKate Legge and Emily Dwyer

Australia: Regulatory exclusivities for pharmaceuticals

The Australian exclusivity regime for medicines differs from those in place in the northern hemisphere. It also contains subtleties that sponsors (originator and generic/biosimilars) need to know to determine the impact on generic/biosimilar market formation.

Already registered?

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@worldipreview.com

More on this story

Patents

Australia extends EPO fast-track patent examinations

21 June 2022 Australia’s IP office, IP Australia, and the European Patent Office (EPO) have agreed to continue the patent prosecution highway (PPH) programme, following a successful pilot phase.

Patents

Australia reverses DABUS AI inventorship ruling

13 April 2022 The Federal Court of Australia has overturned its prior ruling that artificial intelligence (AI) can be a named inventor on a patent application, striking down the last year’s surprising win for Stephen Thaler and his ongoing AI inventorship campaign.

Are you listening, Prime Minister?

Second UPC injunction piles pressure on Disney

‘Engagement and collaboration’: New IP Federation president builds on strong foundations

No mention of IP as Narayan becomes UK’s first Cabinet-level AI Minister

What UK intellectual property wants from the new prime minister

Netlist hits Samsung with second ITC complaint over memory chips

Jones Day welcomes ex-USPTO patent leader in Washington, DC

GenAI patents see ‘full-scale spike’, says WIPO

Australia: Regulatory exclusivities for pharmaceuticals

More on this story

Editor's picks

Editor's picks

More articles